Linus Health

Digital platform for cognitive assessments

Waltham, Massachusetts, United States

About Linus Health

Linus Health improves cognitive care by providing tools for the early detection of Alzheimer's and other forms of dementia using artificial intelligence. Their main product is a digital cognitive assessment platform that combines traditional assessments with AI-driven neurological analysis, allowing for efficient and scientifically validated early detection. Key features include quick iPad-based assessments, automated scoring, and personalized patient action plans. The company's goal is to change the prognosis for patients by enabling earlier and more accurate detection of cognitive impairment.

Waltham, MassachusettsHeadquarters
2019Year Founded
$63.1MTotal Funding
SERIES_BCompany Stage
AI & Machine Learning, Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Health, dental, vision & life insurance
Unlimited PTO
Parental leave
401K with 6% match
Performance Bonus
Employee Stock Purchase Plan
Work From Home Policy
Employee Referral Incentive program
Company Social Outings

Risks

Rapid AI advancements could increase competition from new cognitive assessment tool providers.
Integration challenges from acquiring Together Senior Health may disrupt operations and client relations.
Regulatory scrutiny on AI usability and transparency could impact Linus Health's digital platforms.

Differentiation

Linus Health uses AI to enhance traditional cognitive assessments for early dementia detection.
Their DCTclock is an AI-enhanced upgrade to the traditional clock drawing test.
The platform offers iPad-based assessments with automated scoring and multi-language support.

Upsides

Partnership with Brook Health simplifies cognitive care, enhancing patient and provider experience.
Acquisition of Together Senior Health adds virtual therapeutic solutions to Linus Health's offerings.
Collaboration with uMethod Health integrates personalized care planning into Linus Health's platform.

Funding

Total raised$63.11 M
Latest valuation$275.00 M
StageSERIES_B
$55
$275.00 M
EARLY VC
9/30/2020
$10
$49.40 M